查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863032

感染疾病藥物市場按藥物類別、給藥途徑、適應症、通路和最終用戶分類－2025年至2032年全球預測

Infectious Disease Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，感染疾病治療市場規模將達到 1,731.3 億美元，複合年成長率為 4.55%。

關鍵市場統計數據
基準年 2024 1212.7億美元
預計年份：2025年 1268億美元
預測年份 2032 1731.3億美元
複合年成長率 (%) 4.55%

針對感染疾病藥物領域的簡明策略框架，能夠使相關人員在臨床創新、監管趨勢和營運重點方面達成共識。

感染疾病治療領域正處於關鍵轉折點，這主要得益於分子生物學的進步、疫苗研發進程的加速以及日益複雜的全球供應鏈環境。本導言為研究、生產、臨床實踐和政策等各相關人員提供了策略背景，重點闡述了科學創新與監管合規的融合將如何影響近期決策。我們確立了貫穿整份報告的分析觀點：一種將治療方法、給藥途徑和最終用戶實際情況與營運限制和商業性機會聯繫起來的綜合視角。

後續章節將評估市場動態，探討政策動因和細分市場的具體影響，並將這些因素整合起來，提出優先行動指南。本文重點在於轉化視角：研發管線中的創新成果如何從實驗室走向臨床，生產韌性如何影響產品供應，以及通路如何影響病患在醫療服務點的取得。透過整合技術、監管和商業性因素，本導論為讀者理解後續章節做好準備，並著重闡述對投資、夥伴關係和營運規劃的實際意義。

技術創新、監管現代化和不斷變化的臨床需求正在重新定義感染疾病藥物的研發路徑和商業化策略。

感染疾病藥物領域正經歷著變革性的轉變，這得益於技術突破、新的監管模式以及臨床需求的轉變。基因療法和生物療法日益成熟，單株抗體和細胞激素調節劑不僅成為治療工具，更成為綜合治療方法的重要組成部分。同時，能夠實現快速設計、迭代改進和適應性生產的疫苗技術平台正在重塑針對不同病原體的預防策略。這些技術發展伴隨著數位和診斷技術的進步，使得早期檢測和更有針對性的治療選擇成為可能，從而改變了臨床路徑和支付方的考量。

除了科學層面，監管機構正在採用更靈活的審查機制和緊急使用框架。這些措施加快了產品准入速度，同時要求申辦方致力於更持續的上市後證據收集。因此，商業化策略越來越注重生命週期規劃，力求在加速市場進入和強而有力的真實世界證據項目之間取得平衡。同時，醫療系統正在修訂採購政策和藥品目錄，優先考慮那些不僅具有臨床療效，而且供應穩定可靠、價格合理的藥品。總而言之，這些變化要求企業重組其研發開發平臺、製造地和市場進入策略，以保持競爭力並滿足快速變化的臨床需求。

對 2025 年關稅趨勢對治療領域供應鏈策略、採購決策和在地化生產的影響進行全面分析。

2025年美國關稅政策的累積影響正在重塑整個感染疾病治療生態系統的供應鏈經濟、採購行為和策略採購決策。關稅變化直接影響了原料藥、某些生物製藥以及商業生產和研發所必需的試劑的成本。由此帶來的單位經濟效益壓力正促使製造商重新考慮供應商多元化、庫存持有策略以及近岸外包方案，以降低進口相關成本波動帶來的風險。

為因應這項挑戰，具有前瞻性的企業正在加速投資本地生產能力，並與合約研發生產機構（CDMO）建立策略聯盟，以增強區域韌性。這些措施旨在保護生產免受關稅導致的利潤率下降的影響，同時確保高優先級產品能夠快速上市。此外，採購部門正在採取更精細的成本控制措施，重新談判長期契約，並採用總落地成本分析，而不僅僅是單位成本分析。監管機構和醫保報銷相關人員也出現了類似的趨勢。支付者正在更密切地審查成本促進因素，醫療系統正在將供應鏈風險評估納入藥品目錄編制決策中。

最後，關稅環境凸顯了政策參與的重要性。產業相關人員正積極解釋貿易措施對臨床實踐和公共衛生的下游影響，並努力推動調整，以確保患者獲得治療並維持生產競爭力。整體而言，2025 年的關稅環境不僅導致成本負擔的重​​新分配，也推動了整個治療價值鏈中採購、生產策略和相關人員合作的結構性變革。

透過對治療領域、給藥途徑、臨床適應症、通路和終端用戶趨勢進行綜合觀點，明確優先順序。

細分市場分析揭示了產品、劑量和臨床應用的差異，從根本上改變了藥物研發和商業化策略。從抗生素、抗真菌藥物、抗病毒藥、生物製藥和疫苗等藥物類別來看，每一類都存在獨特的臨床和生產方面的考量。抗生素在包括Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類和四環黴素在內的各種亞類中仍然非常重要，每種抗生素都有其獨特的抗藥性動態和用藥管理要求，這些都會影響臨床指南和採購政策。抗真菌藥物（包括Azole、Echinocandins和Polyenes）在診斷和劑量複雜性方面面臨獨特的挑戰，這些挑戰影響醫院處方集的採納和門診治療路徑。抗病毒藥物，包括整合酶抑制劑、神經氨酸酶抑制劑、核苷類似物和蛋白酶抑制劑，具有治療特異性和抗藥性特徵，這些特徵推動了聯合用藥策略和依從性干預措施的發展。

生物製藥，包括細胞激素和單株抗體，需要複雜的低溫運輸物流和生產控制策略，這與小分子藥物截然不同。同時，結合疫苗、去活化疫苗、減毒活病毒疫苗和次單位疫苗等疫苗類型也需要獨特的生產設施、低溫運輸要求和監管文件。給藥途徑是關鍵的細分維度：吸入、靜脈注射、口服和局部用藥會影響病患依從性、臨床經濟性和分銷管道的適用性。按適應症進行細分可以進一步最佳化策略選擇。不同的治療領域，例如 COVID-19、胃腸道感染疾病、肝炎、HIV/AIDS、呼吸道感染疾病、皮膚感染疾病和尿道感染感染，分別驅動著不同的臨床試驗設計、真實世界證據需求和與支付者的互動。分銷管道的差異——醫院藥房、線上藥房和零售藥房——塑造供應模式和上市後監測路徑。同時，最終用戶細分（診所、居家醫療和醫院）決定了服務交付模式、容量規劃和支援服務需求。

整合這些細分維度，能夠幫助相關人員識別：未滿足的臨床需求與有利的產品屬性相交的領域、生產複雜性與報銷潛力相交的領域，以及給藥途徑創新能夠開闢新途徑的領域。這種整合的細分觀點有助於更精準地確定投資組合的優先順序、更有針對性地與臨床和支付相關利益者互動，以及製定能夠反映具體應用場景實際情況的最佳化分銷策略。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、生產能力和醫療保健系統優先事項將如何決定醫療服務的可近性和策略重點？

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管時間表、生產策略和病患用藥途徑有重大影響。在美洲，法規環境各不相同，從核准途徑嚴格的高度集中體係到可能延緩跨境用藥的分散式司法管轄結構，不一而足。這種多樣性要求制定差異化的市場進入策略、策略定價方案以及保障供應連續性的緊急時應對計畫。在歐洲、中東和非洲地區，相關人員必須應對複雜的監管方法、報銷框架和公共衛生優先事項。在此，聯合採購機制和區域疾病負擔在產品推廣和公開競標中發揮關鍵作用。

亞太地區擁有成熟市場和快速發展市場並存的多元化格局，多個經濟體具備強大的本地製造能力，對先進生物製藥和價格適中的小分子藥物的需求日益成長。該地區的政策促進因素通常優先考慮關鍵藥物的自給自足，鼓勵對國內生產和技術轉移進行投資。不同地區的醫療體系資金籌措機制、公共衛生優先事項和物流限制各不相同，這決定了對低溫運輸基礎設施、照護現場診斷和分散式供應模式的投資在哪些地區能夠發揮最大作用。重要的是，區域監管協調工作和多邊採購舉措有望降低創新治療方法的進入門檻，前提是申辦方能夠調整其申請和證據產生策略，以滿足多個司法管轄區的要求。

感染疾病治療領域的成功促進因素是科學差異化、生產策略和夥伴關係模式的競爭格局。

感染疾病治療領域中主要企業之間的競爭動態是由科學差異化、生產規模和夥伴關係彈性三者共同驅動的。成熟的跨國公司繼續利用其豐富的研發管線和全球生產網路，支持後期研發和大規模商業性化上市。同時，規模較小的生技公司則傾向於專注於獨特的作用機製或可授權或合作開發的平台技術。合約研發生產機構（CDMO）作為策略推動者，提供靈活的產能和生物製藥及疫苗生產方面的專業知識，從而幫助缺乏固定生產資產的申辦方加快臨床試驗的啟動。

縱觀整個產業格局，成功的企業正在採用多種經營模式的組合。有些企業優先考慮對生產進行垂直整合控制，以確保供應鏈的穩定性；而有些企業則採取輕資產模式，透過外部夥伴關係強調速度和產品組合的廣度。從用於藥物警戒的高級分析到遠端患者監護和用藥依從性平台，數位技術正被擴大用於差異化商業性提案並支持與支付方的互動。治療藥物開發商、診斷公司和分銷合作夥伴之間的策略聯盟也日益普遍，這反映出人們認知到，整合解決方案可以改善臨床結果並簡化醫療系統的採購流程。總而言之，那些兼具科學嚴謹性、營運適應性和協作式市場推廣策略的企業正在競爭激烈的市場環境中佔據優勢。

為產業領導者提供切實可行的優先行動方案，以加強其治療產品組合的供應韌性、證據產生和以患者為中心的市場進入。

產業領導者應採取優先且切實可行的措施，以應對不斷變化的科學、監管和供應鏈現實。首先，企業應將供應鏈韌性作為核心策略目標，具體措施包括供應商多元化、尋求區域性生產方案以及建立緊急庫存體系。這些措施將有助於降低貿易政策波動帶來的風險，並確保醫療服務的連續性。其次，將真實世界證據的生成融入產品上市及上市後活動中，將有助於加快支付方的接受度，並支持靈活的監管路徑。為此，各機構應投資於數位資料收集工具和跨相關人員的證據合作，以確保獲得高品質的長期結果數據。

第三，商業策略必須日益重視給藥途徑和終端使用者偏好。開發以患者為中心的製劑和給藥方案，支持居家醫療和門診護理，可以轉變用藥模式，使患者和支付方都從中受益。第四，應積極尋求與契約製造、診斷公司和區域經銷商建立策略聯盟，以應對產能限制並簡化市場進入。最後，企業應優先與政策制定者和採購機構進行透明對話，溝通臨床價值以及貿易和關稅政策對市場准入的影響。全面實施這些措施，將有助於平衡短期業務需求與長期價值創造和市場韌性。

採用透明的多方法研究途徑，結合專家訪談、二手證據檢驗驗證和檢驗程序，確保研究結果具有可操作性和可重複性。

本分析的調查方法結合了多源證據綜合、專家訪談以及嚴格的檢驗通訊協定，以確保研究結果的穩健性和相關性。主要資料來源包括對臨床醫生、供應鏈高管、監管專家和商業領袖的結構化訪談，旨在收集關於臨床實踐、採購決策和生產策略的一線觀點。這些質性研究結果與包括同儕審查的臨床文獻、已發布的監管指導文件和公司檢驗在內的二手資料進行三角驗證，從而建立起基於事實的治療方法特徵和監管趨勢的基礎。

為確保分析的嚴謹性，研究結果透過與專家和技術負責人的反覆諮詢進行交叉檢驗，這些專家和技術審查人員評估了有關臨床實施、生產複雜性和分銷物流的假設。數據品管包括資訊來源核實、對受訪者進行利益衝突篩檢，以及記錄如何將一手和二手資訊納入分析結論的審核追蹤。方法論強調透明度和可重複性，詳細的附錄包括訪談通訊協定、二級資訊來源選擇標準和細分軸定義，使讀者能夠評估策略建議的依據，並將這些見解應用於自身的營運環境。

整合以韌性、實證市場進入和營運誠信為核心的策略要務，以推動技術應用並改善病患療效。

總之，感染疾病治療領域正受到多種因素的共同影響而重塑：快速的科學創新、不斷變化的監管要求以及受關稅調整等政策變化影響的供應鏈現狀。這些趨勢對價值鏈上的相關人員——包括研發人員、製造商、支付者和醫療保健系統——提出了挑戰，要求他們採取整合策略，將科學差異化與營運韌性相結合。本報告提出的細分框架闡明了治療特性、給藥途徑、臨床適應症和分銷管道的交匯點，從而形成了獨特的策略要務。

成功的組織能夠將技術創新轉化為可擴展的生產和供應模式，同時保持靈活且基於實證的市場進入策略。與監管機構和採購相關人員積極合作、對製造和數據基礎設施進行有針對性的投資以及創造性的夥伴關係模式，對於保持競爭優勢至關重要。本文提出的綜合分析旨在透過強調在降低風險、加速技術應用和改善患者預後等方面，如何最有效地利用資源和資金，從而支持明智的決策，並涵蓋各種感染疾病防治重點領域。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 加速研發基於mRNA的疫苗，用於預防季節性和新出現的呼吸道病毒
  • 越來越多的免疫力缺乏新冠肺炎患者開始接受長效單株抗體預防治療。
  • 在三級醫療機構中整合基於 CRISPR 的快速診斷和個人化抗生素管理
  • 頻譜病毒聚合酵素抑制劑在控制流行性呼吸道病原體方面的臨床進展
  • 口服直接抗病毒藥物的出現，針對慢性D型肝炎肝炎病毒感染，為治療慢性B型肝炎提供了新的思路。
  • 生物導向療法的創新：調節先天免疫和降低敗血症相關死亡率
  • 在臨床試驗中設計合成抗菌肽以對抗多重抗藥性細菌感染疾病

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章感染疾病藥物市場（依藥物類別分類）

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺類
    • Fluoroquinolones
    • 大環內酯類
    • 四環黴素
  • 抗真菌藥物
    • Azole
    • Echinocandins
    • Polyenes
  • 抗病毒藥物
    • 整合酶抑制劑
    • 神經氨酸酶抑制劑
    • 核苷類似物
    • 蛋白酶抑制劑
  • 生物製藥
    • 細胞激素
    • 單株抗體
  • 疫苗
    • 組合型
    • 失活
    • 活病毒疫苗
    • 次單元

第9章感染疾病藥物市場（依給藥途徑分類）

  • 吸入
  • 靜脈注射
  • 口服
  • 局部用藥

第10章感染疾病藥物市場（依適應症分類）

  • COVID-19
  • 胃腸道感染疾病
  • 肝炎
  • 愛滋病毒/愛滋病
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 尿道感染

第11章感染疾病藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章感染疾病藥物市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第13章 各地區感染疾病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章感染疾病藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國感染疾病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • AstraZeneca plc
    • AbbVie Inc.
    • Novartis AG
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market is projected to grow by USD 173.13 billion at a CAGR of 4.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 121.27 billion
Estimated Year [2025] USD 126.80 billion
Forecast Year [2032] USD 173.13 billion
CAGR (%) 4.55%

Concise strategic framing of the infectious disease therapeutics environment to orient stakeholders around clinical innovation, regulatory dynamics, and operational priorities

The infectious disease therapeutics landscape is at a pivotal inflection point driven by advances in molecular biology, accelerated vaccine development pathways, and an increasingly complex global supply environment. This introduction frames the strategic context for stakeholders across research, manufacturing, clinical practice, and policy, emphasizing the confluence of scientific innovation and regulatory adaptation that shapes near-term decisions. It establishes the analytical lens used throughout this report: an integrated view that links therapeutic modality, route of administration, and end-user realities to operational constraints and commercial opportunity.

In the following sections, the reader will encounter assessments of market dynamics, policy shocks, and segmentation-specific implications that collectively inform high-priority actions. The narrative prioritizes translational considerations: how pipeline innovations move from lab to clinic, how manufacturing resilience influences product availability, and how distribution channels modulate access at the point of care. By synthesizing technical, regulatory, and commercial vectors, this introduction prepares the reader to interpret downstream chapters with a focus on practical implications for investment, partnership, and operational planning.

How converging technological advances, regulatory modernization, and shifting clinical demand are redefining development pathways and commercialization strategies for infectious disease therapies

Transformative shifts in infectious disease therapeutics are unfolding through technological breakthroughs, novel regulatory paradigms, and shifting patterns of clinical demand. Gene-based and biologic approaches have matured to the point where monoclonal antibodies and cytokine modulators are not only therapeutic tools but also essential components of integrated treatment regimens. Concurrently, vaccine technology platforms that enable rapid design, iterative improvements, and adaptive manufacturing are reshaping prevention strategies across diverse pathogen classes. These technical developments are accompanied by digital and diagnostic advances that allow for earlier detection and more targeted therapy selection, thereby altering clinical pathways and payer considerations.

Beyond science, regulatory agencies have adopted more flexible review mechanisms and emergency-use frameworks that, while expediting access, require sponsors to engage in more continuous post-market evidence generation. As a result, commercialization strategies increasingly require lifecycle planning that balances accelerated entry with robust real-world evidence programs. In parallel, health systems are recalibrating procurement and formularies to favor products that demonstrate not only clinical efficacy but also demonstrable supply resilience and affordability. Taken together, these shifts demand that companies re-architect R&D pipelines, manufacturing footprints, and market access approaches to remain competitive and responsive to rapidly evolving clinical needs.

Comprehensive analysis of how 2025 tariff developments are recalibrating supply chain strategies, procurement decisions, and manufacturing localization across therapeutics

The cumulative effects of United States tariff policy developments in 2025 are shaping supply-chain economics, procurement behaviors, and strategic sourcing decisions across the infectious disease therapeutics ecosystem. Tariff changes have had a direct bearing on the cost of active pharmaceutical ingredients, certain biologics inputs, and reagents critical to both commercial manufacturing and research operations. The resulting pressure on unit economics has compelled manufacturers to revisit supplier diversification, inventory stocking policies, and nearshoring alternatives to mitigate exposure to import-related cost volatility.

In response, forward-looking organizations have accelerated investments in localized manufacturing capabilities and strategic partnerships with contract development and manufacturing organizations that offer regional resiliency. These moves are intended to insulate production from tariff-induced margin erosion while preserving speed-to-market for high-priority products. Additionally, procurement teams have adopted more granular cost-control measures, renegotiating long-term contracts and applying total landed cost analysis rather than price-per-unit alone. Regulatory and reimbursement stakeholders have likewise taken notice: payers are scrutinizing cost drivers more closely, and health systems are incorporating supply-chain risk assessments into formulary decisions.

Finally, the tariff environment has amplified the importance of policy engagement. Industry participants are increasingly proactive in articulating the downstream clinical and public-health implications of trade measures, aiming to inform adjustments that preserve patient access and maintain manufacturing competitiveness. Overall, the 2025 tariff context has not only reallocated cost burdens but also catalyzed structural shifts in sourcing, manufacturing strategy, and stakeholder alignment across the therapeutic value chain.

Integrated segmentation perspective connecting therapeutic class, administration route, clinical indication, distribution channel, and end-user dynamics to inform prioritization

Segmentation analysis illuminates product, administration, and clinical-use distinctions that fundamentally alter development and commercialization approaches. When viewed through drug class lenses such as antibiotics, antifungals, antivirals, biologics, and vaccines, each category presents unique clinical and manufacturing considerations. Antibiotics retain importance across diverse sub-classes including aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines, each with differing resistance dynamics and stewardship imperatives that influence clinical guidelines and procurement preferences. Antifungal therapies, encompassing azoles, echinocandins, and polyenes, face distinct diagnostics and dosing complexities that shape hospital formulary uptake and outpatient treatment pathways. Antiviral agents such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors exhibit therapeutic specificity and resistance profiles that drive combination strategies and adherence interventions.

Biologics, including cytokines and monoclonal antibodies, require sophisticated cold-chain logistics and manufacturing control strategies that differentiate them from small-molecule agents, while vaccine types such as conjugate, inactivated, live attenuated, and subunit platforms each demand tailored manufacturing footprints, cold-chain requirements, and regulatory dossiers. Route of administration is a pivotal segmentation axis: inhalation, intravenous, oral, and topical modalities affect patient adherence, site-of-care economics, and distribution channel suitability. Indication-specific segmentation further refines strategic choices; therapeutic focus areas such as COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections create distinct clinical trial designs, real-world evidence needs, and payer conversations. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy shape fulfillment models and post-market surveillance pathways, while end-user segmentation - clinics, homecare, and hospitals - determines service delivery models, capacity planning, and support-service requirements.

Bringing these segmentation dimensions together enables stakeholders to identify where clinical unmet needs intersect with advantageous product characteristics, where manufacturing complexity aligns with reimbursement potential, and where route-of-administration innovations can unlock new access pathways. This integrated segmentation perspective supports more precise prioritization of portfolio investments, targeted engagement with clinical and payer stakeholders, and optimized distribution strategies that reflect distinct use-case realities.

How regional regulatory diversity, manufacturing capacity, and health-system priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific determine access and strategic focus

Regional dynamics exert a material influence on regulatory timelines, manufacturing strategy, and patient access across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory environments vary from highly centralized systems with robust approval pathways to fragmented jurisdictional landscapes that can slow cross-border access; this diversity necessitates differentiated market-entry tactics, strategic pricing discussions, and contingency plans for supply continuity. In the Europe Middle East & Africa context, stakeholders must navigate a mosaic of regulatory approaches, reimbursement frameworks, and public-health priorities, where collaborative procurement mechanisms and regional disease burden profiles play a significant role in adoption curves and public tenders.

Asia-Pacific presents a dynamic mix of established and rapidly evolving markets, with strong local manufacturing capacity in several economies and growing demand for both advanced biologics and accessible small-molecule therapies. Policy drivers in this region often prioritize self-reliance in critical medicines, fostering investment in domestic production and technology transfer. Across regions, differences in health-system funding mechanisms, public-health priorities, and logistical constraints shape where investment in cold-chain infrastructure, point-of-care diagnostics, and decentralized delivery models will yield the greatest returns. Importantly, regional regulatory harmonization efforts and multilateral procurement initiatives have the potential to lower barriers to entry for innovative therapies, provided that sponsors align dossiers and evidence-generation strategies to meet cross-jurisdictional requirements.

Key competitive patterns revealing how scientific differentiation, manufacturing strategy, and partnership models drive success in infectious disease therapeutics

Competitive dynamics among leading companies in infectious disease therapeutics are driven by a combination of scientific differentiation, manufacturing scale, and partnership agility. Established multinational firms continue to leverage deep pipelines and global manufacturing networks to support late-stage development and broad commercial launches, while smaller biotechnology companies often focus on niche mechanisms of action or platform technologies that can be licensed or co-developed. Contract development and manufacturing organizations have become strategic enablers, offering flexibility in capacity and specialized know-how for biologic and vaccine production, which accelerates time-to-clinic for sponsors without fixed manufacturing assets.

Across the landscape, successful companies deploy a mix of business models: some prioritize vertically integrated control over manufacturing to ensure supply resilience, while others pursue asset-light approaches that emphasize speed and portfolio breadth through external partnerships. Digital capabilities-ranging from advanced analytics for pharmacovigilance to remote patient monitoring and adherence platforms-are increasingly used to differentiate commercial propositions and support payer dialogues. Strategic alliances between therapeutic developers, diagnostic firms, and distribution partners are also more common, reflecting a recognition that bundled solutions can improve clinical outcomes and simplify procurement for health systems. In sum, the competitive landscape rewards organizations that combine scientific rigor with operational adaptability and collaborative go-to-market strategies.

Practical high-priority actions for industry leaders to strengthen supply resilience, evidence generation, and patient-centric market access across therapeutic portfolios

Industry leaders should adopt a set of prioritized, actionable measures to navigate evolving scientific, regulatory, and supply-chain realities. First, companies must embed supply resilience as a core strategic objective by diversifying supplier bases, pursuing regional manufacturing options, and formalizing contingency inventories; such measures reduce exposure to trade-policy shocks and maintain continuity of care. Second, integrating real-world evidence generation into launch and post-marketing activities will accelerate payer acceptance and support adaptive regulatory pathways, so organizations should invest in digital data capture tools and cross-stakeholder evidence partnerships to ensure high-quality, longitudinal outcome data.

Third, commercial strategies must increasingly account for route-of-administration and end-user preferences; developing patient-centric formulations or delivery options that enable homecare and outpatient treatment can shift utilization patterns in a way that benefits both patients and payers. Fourth, strategic partnerships with contract manufacturers, diagnostics firms, and regional distributors should be pursued proactively to manage capacity constraints and streamline market access. Finally, companies should prioritize transparent engagement with policymakers and procurement bodies to communicate clinical value and the implications of trade or tariff policies on access. Collectively, these actions balance short-term operational imperatives with long-term value creation and resilience.

Transparent multi-method research approach combining expert interviews, secondary evidence triangulation, and validation procedures to ensure actionable and reproducible insights

The research methodology underpinning this analysis combined multi-source evidence synthesis, targeted expert engagement, and rigorous validation protocols to ensure robustness and relevance. Primary inputs included structured interviews with clinicians, supply-chain executives, regulatory specialists, and commercial leaders to capture first-hand perspectives on clinical practice, procurement decision-making, and manufacturing strategy. These qualitative insights were triangulated with secondary source materials such as peer-reviewed clinical literature, publicly available regulatory guidance documents, and company disclosures to establish a factual baseline for therapeutic modality characteristics and regulatory trends.

To ensure analytical rigor, findings were cross-validated through iterative consultations with subject-matter experts and technical reviewers who assessed assumptions about clinical adoption, manufacturing complexity, and distribution logistics. Data quality controls included source provenance checks, conflict-of-interest screening for interview participants, and an audit trail documenting how primary and secondary inputs informed each analytical conclusion. The methodology emphasizes transparency and reproducibility; detailed appendices provide interview protocols, inclusion criteria for secondary sources, and definitions for segmentation axes so that readers can evaluate the basis for strategic recommendations and adapt insights to their own operational contexts.

Synthesis of strategic imperatives emphasizing resilience, evidence-driven market access, and operational alignment to accelerate adoption and improve patient outcomes

In conclusion, infectious disease therapeutics are being reshaped by intersecting forces: rapid scientific innovation, evolving regulatory expectations, and supply-chain realities intensified by policy shifts such as tariff adjustments. These dynamics demand that stakeholders across the value chain-developers, manufacturers, payers, and health systems-adopt integrated strategies that align scientific differentiation with operational resilience. The segmentation framework presented in this report clarifies where therapeutic characteristics, administration routes, clinical indications, and distribution channels converge to create distinct strategic imperatives.

Looking ahead, success will favor organizations that can translate technical innovations into scalable production and delivery models while maintaining flexible, evidence-driven approaches to market access. Proactive engagement with regulatory and procurement stakeholders, targeted investments in manufacturing and data infrastructure, and creative partnership models will be central to sustaining competitive advantage. The synthesis provided here is intended to support informed decision-making by highlighting where effort and capital can most effectively reduce risk, accelerate adoption, and ultimately improve patient outcomes across diverse infectious disease priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Accelerated development of mRNA-based vaccines for seasonal and emerging respiratory virus prevention
  • 5.2. Increased adoption of long-acting monoclonal antibodies for prophylaxis in immunocompromised COVID-19 patients
  • 5.3. Integration of CRISPR-based rapid diagnostics with bespoke antibiotic stewardship in tertiary care hospitals
  • 5.4. Clinical advancement of broad-spectrum viral polymerase inhibitors for pandemic respiratory pathogen readiness
  • 5.5. Emergence of oral direct-acting antivirals targeting hepatitis delta co-infection in chronic hepatitis B regimes
  • 5.6. Innovation in host-directed therapies aiming to modulate innate immunity and reduce sepsis-related mortality
  • 5.7. Engineering synthetic antimicrobial peptides to overcome multidrug-resistant bacterial infections in clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Disease Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antivirals
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Neuraminidase Inhibitors
    • 8.3.3. Nucleoside Analogues
    • 8.3.4. Protease Inhibitors
  • 8.4. Biologics
    • 8.4.1. Cytokines
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Conjugate
    • 8.5.2. Inactivated
    • 8.5.3. Live Attenuated
    • 8.5.4. Subunit

9. Infectious Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Infectious Disease Therapeutics Market, by Indication

  • 10.1. COVID-19
  • 10.2. Gastrointestinal Infections
  • 10.3. Hepatitis
  • 10.4. HIV/AIDS
  • 10.5. Respiratory Infections
  • 10.6. Skin Infections
  • 10.7. Urinary Tract Infections

11. Infectious Disease Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Infectious Disease Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare
  • 12.3. Hospitals

13. Infectious Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Infectious Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. F. Hoffmann-La Roche Ltd
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. GlaxoSmithKline plc
    • 16.3.7. Sanofi S.A.
    • 16.3.8. AstraZeneca plc
    • 16.3.9. AbbVie Inc.
    • 16.3.10. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKE